Dr. Nabil Noureddin (Medicine) recently presented his project at the Digital International Liver Congress 2020. The abstract, “The Accuracy of the FAST Score in Predicting Nonalcoholic Steatohepatitis (NASH) with Significant Fibrosis,” was published in the Journal of Hepatology.
NASH is estimated to increase from 16.52 million to 27.00 million in the U.S. alone. Recent data showed that the FAST score is highly accurate in predicting NASH patients who have NAFLD activity score of ≥ 4 and Fibrosis ≥ 2 (NAS4F2). Noureddin and his co-authors aims were to validate the FAST score and to assess its performance in various patients’ subgroups. They performed a cross-sectional analysis and found that the FAST score is an accurate score in predicting NAS4F2 and its accuracy didn’t vary by diabetes status. Based on the study FAST score accuracy ranges between very good to excellent depending on BMI.
The clinical significance of the study is that it adds to the efforts in improving non-invasive tests that are used to identify patients who are eligible for NASH clinical trials.
